CoChat
Sign Up
Cited by 2Bacteriophages and microbial interactionsNanoparticle-Based Drug DeliveryVirus-based gene therapy research

New role of bacteriophages in medical oncology

Open access
Moradi, Mohammad, Ghaleh, Hadi Esmaeili Gouvarchin, Bolandian, Masoumeh, Dorostkar, Ruhollah·2023·Biotechnology and Applied Biochemistry
DOI 10.1002/bab.2506
Open this paper in CoChat — free accountOpen PDF

Abstract

Targeted treatment of cancer is one of the most paramount approaches in cancer treatment. Despite significant advances in cancer diagnosis and treatment methods, there are still significant limitations and disadvantages in the field, including high costs, toxicity, and unwanted damage to healthy cells. The phage display technique is an innovative method for designing carriers containing exogenic peptides with cancer diagnostic and therapeutic properties. Bacteriophages possess unique properties making them effective in cancer treatment. These characteristics include the small size enabling them to penetrate vessels; having no pathogenicity to mammals; easy manipulation of their genetic information and surface proteins to introduce vaccines and drugs to cancer tissues; lower cost of large‐scale production; and greater stimulation of the immune system. Bacteriophages will certainly play a more effective role in the future of medical oncology; however, studies are in the early stages of conception and require more extensive research. We aimed in this review to provide some related examples and bring insights into the potential of phages as targeted vectors for use in cancer diagnosis and treatment, especially regarding their capability in gene and drug delivery to cancer target cells, determination of tumor markers, and vaccine design to stimulate anticancer immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bab.2506

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 49

  1. Bakhshinejad B, Karimi M, Sadeghizadeh M. Bacteriophages and medical oncology: targeted gene therapy of cancer. Med Oncol. 2014;31(8):1-11.
  2. Dabrowska K, Opolski A, Wietrzyk J, Switala-Jelen K, Godlewska J, Boratynski J, et al. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res. 2004;24(6):3991-3996.
  3. Budynek P, Dąbrowska K, Skaradziński G, Górski A. Bacterio- phages and cancer. Arch Microbiol. 2010;192(5):315-320.
  4. Uchiyama F, Tanaka Y, Minari Y, Tokui N. Designing scaf- folds of peptides for phage display libraries. J Biosci Bioeng. 2005;99(5):448-456.
  5. Somiya M, Kuroda S'. Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule. Adv Drug Deliv Rev. 2015;95:77-89.
  6. Zhu S, Huang AG, Luo F, Li J, Li J, Zhu L, et al. Application of virus targeting nanocarrier drug delivery system in virus- induced central nervous system disease treatment. ACS Appl Mater Interfaces. 2019;11(21):19006-19016.
  7. Mansour A, Romani M, Acharya AB, Rahman B, Verron E, Badran Z. Drug Delivery Systems in Regenerative Medicine: An Updated Review. Pharmaceutics. 2023;15(2):695.
  8. Yue H, Li Y, Yang M, Mao C. T7 phage as an emerging nanobio- material with genetically tunable target specificity. Adv Sci. 2022;9(4):2103645.
  9. Amin S, Bathe OF. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer. 2016;16(1):1-11.
  10. Hait WN. Targeted cancer therapeutics. Cancer Res. 2009;69(4):1263-1267.
  11. Wu C-H, Liu I-Ju, Lu R-M, Wu H-C. Advancement and applica- tions of peptide phage display technology in biomedical science. J Biomed Sci. 2016;23(1):1-14.
  12. Yao VJ, D'angelo S, Butler KS, Theron C, Smith TL, Marchiò S, et al. Ligand-targeted theranostic nanomedicines against cancer. J Controlled Release. 2016;240:267-286.
  13. Lammers T, Rizzo LY, Storm G, Kiessling F. Personalized NanomedicinePersonalized Nanomedicine. Clin Cancer Res. 2012;18(18):4889-4894.
  14. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651-659.
  15. Haseley A, Alvarez-Breckenridge C, Chaudhury A, Kaur B. Advances in oncolytic virus therapy for glioma. Recent Patents on CNS Drug Discovery (Discontinued). 2009;4(1):1-13.
  16. Switała-Jelen K, Opolski A, Weber-Dabrowska B, & Gorski A. Bacteriophage penetration in vertebrates. J Appl Microbiol. 2005;98:7-13.
  17. Li X-Bo, Schluesener HJ, Xu S-Q. Molecular addresses of tumors: selection by in vivo phage display. Arch Immunol Ther Exp (Warsz). 2006;54(3):177-181.
  18. Lorch A. Bacteriophages: An alternative to antibiotics. Biotech- nol Dev Monit. 1999;39:14-17.
  19. Kulseth MA, Fagerlund A, Myrset AH. Affinity selection using filamentous phage display, in Therapeutic Peptides. 2014, Springer. p. 67-80.
  20. Bábíčková J, Tóthová Ľ, Boor P, Celec P. In vivo phage display- A discovery tool in molecular biomedicine. Biotechnol Adv. 2013;31(8):1247-1259.
  21. Phage FF. Novel Expression Vectors That Display Cloned Anti- gens On The Virion Surface, G. Smith. Science. 1985;228:1315- 1316.
  22. Malys N, Chang D-Y, Baumann RG, Xie D, Black LW. A bipar- tite bacteriophage T4 SOC and HOC randomized peptide display library: detection and analysis of phage T4 terminase (gp17) and late σ factor (gp55) interaction. J Mol Biol. 2002;319(2):289-304.
  23. Pires DP, Costa AR, Pinto G, Meneses L, & Azeredo J. Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev. 2020;44(6):684-700.
  24. Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol. 2019;10:513.
  25. Ju Z, Sun W. Drug delivery vectors based on filamentous bacteriophages and phage-mimetic nanoparticles. Drug Deliv. 2017;24(1):1898-1908.
  26. Fukuda MN. Peptide-displaying phage technology in glycobiol- ogy. Glycobiology. 2012;22(3):318-325.
  27. Brown R, Lengeling A, Wang B. Phage engineering: how advances in molecular biology and synthetic biology are being utilized to enhance the therapeutic potential of bacteriophages. Quantitative Biology. 2017;5(1):42-54.
  28. Sanmukh SG, Felisbino SL. Bacteriophages in cancer biology and therapies. Clin Oncol. 2017;2:1295.
  29. Lee S-Y, Ferrari M, Decuzzi P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnol- ogy. 2009;20(49):495101.
  30. Chauhan VP, Popović Z, Chen Ou, Cui J, Fukumura D, Bawendi MG, et al. Fluorescent nanorods and nanospheres for real- time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem. 2011;123(48):11619-11622.
  31. Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeu- tic peptides for cancer treatment. J Biomed Sci. 2017;24(1):1-15.
  32. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvi- ronment (TIME) for effective therapy. Nat Med. 2018;24(5):541- 550.
  33. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncol- ogy. Nat Rev Clin Oncol. 2017;14(7):399-416.
  34. Borysowski J, Górski A. Phage-display technology and its appli- cation to experimental oncological therapy. Postepy Higieny i Medycyny Doswiadczalnej (Online). 2004;58:100-107.
  35. Wada A, Terashima T, Kageyama S, Yoshida T, Narita M, Kawauchi A, et al. Efficient prostate cancer therapy with tissue- specific homing peptides identified by advanced phage display technology. Molecular Therapy-Oncolytics. 2019;12:138-146.
  36. Cai X-M, Xie H-L, Liu M-Z, Zha Xi-L. Inhibition of cell growth and invasion by epidermal growth factor-targeted phagemid particles carrying siRNA against focal adhesion kinase in the presence of hydroxycamptothecin. BMC Biotech. 2008;8(1):1-7.
  37. Tsafa E, Bentayebi K, Topanurak S, Yata T, Przystal J, Fongmoon D, et al. Doxorubicin improves cancer cell targeting by filamen- tous phage gene delivery vectors.Int J Mol Sci. 2020;21(21):7867.
  38. Przystal JM, Waramit S, Pranjol MdZI, Yan W, Chu G, Chongchai A, et al. Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma. EMBO Mol Med. 2019;11(4):e8492.
  39. Garg P. Filamentous bacteriophage: A prospective platform for targeting drugs in phage-mediated cancer therapy. Journal of Cancer Research and Therapeutics. 2019;15(8):1.
  40. Gaubin M, Fanutti C, Mishal Z, Durrbach A, De Berardinis P, Sartorius R, et al. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol. 2003;22(1):11-18.
  41. González-Mora A, Hernández-Pérez J, Iqbal HMN, Rito- Palomares M, Benavides J. Bacteriophage-based vaccines: A potent approach for antigen delivery. Vaccines. 2020;8(3):504.
  42. Ulivieri C, Citro A, Ivaldi F, Mascolo D, Ghittoni R, Fanigliulo D, et al. Antigenic properties of HCMV peptides displayed by fil- amentous bacteriophages vs. synthetic peptides. Immunol Lett. 2008;119(1-2):62-70.
  43. Barati N, Razazan A, Nicastro J, Slavcev R, Arab A, Mosaffa F, et al. Immunogenicity and antitumor activity of the super- lytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Lett. 2018;424:109-116.
  44. Asadi-Ghalehni M, Rasaee MJ, Namvar Asl N, Khosravani M, Rajabibazl M, Khalili S, et al. Construction of a recombinant phage-vaccine capable of reducing the growth rate of an estab- lished LL2 tumor model. Iranian Journal of Allergy, Asthma and Immunology. 2018;240-249.
  45. Li C, Li J, Xu Y, Zhan Y, Li Yu, Song T, et al. Application of Phage-displayed peptides in tumor imaging diagnosis and targeting therapy. Int J Pept Res Ther. 2021;27:587-595.
  46. Yi H, Ghosh D, Ham M-Ho, Qi J, Barone PW, Strano MS, et al. M13 phage-functionalized single-walled carbon nanotubes as nanoprobes for second near-infrared window fluorescence imaging of targeted tumors. Nano Lett. 2012;12(3):1176-1183.
  47. Baurand P-E, Balland J, Reynas C, Ramseyer M, Vivier D, Bellaye P-S, et al. Development of Anti-LRRC15 Small Frag- ments for Imaging Purposes Using a Phage-Display ScFv Approach. Int J Mol Sci. 2022;23(20):12677.
  48. Tsedev U, Lin C-W, Hess GT, Sarkaria JN, Lam FC, Belcher AM. Phage Particles of Controlled Length and Genome for In Vivo Targeted Glioblastoma Imaging and Therapeutic Delivery. ACS nano. 2022;16(8):11676-11691.
  49. Arab A, Nicastro J, Slavcev R, Razazan A, Barati N, Nikpoor AR, et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunol Res. 2018;66(1):200-206.

Cited by

Sorted by citations

Authors
Moradi, M., Ghaleh, H. E. G., Bolandian, M., & Dorostkar, R.
Affiliations
Baqiyatallah University of Medical Sciences (IR)
Corresponding author
Dorostkar, Ruhollah
ORCID
Venue
Biotechnology and Applied Biochemistry
Publisher
Wiley
Published
2023-08-28
Volume
70
Issue
6
Pages
2017-2024
ISSN
  • 0885-4513 (ISSN-L)
  • 1470-8744
DOI
10.1002/bab.2506
OpenAlex
W4386209284
Cited by
2
References
0
Citations by year
2026: 1 · 2025: 1
FWCI
0.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Biotechnology and Applied Biochemistry (publishedVersion, other-oa)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
bacteriophages, phage display, targeted cancer therapy, phage vectors, gene delivery, drug delivery, tumor markers, antitumor immunity, cancer diagnosis
MeSH terms
Animals, Bacteriophages, Pharmaceutical Preparations, Humans, Mammals, Medical Oncology, Neoplasms, Vaccines, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review